Xoma Corporation

About the Company

XOMA Corporation doesn’t want to toil in anonymity. Instead, the company pairs with larger drug firms to develop and market its products, primarily monoclonal antibodies (biotech drugs based on cloned proteins). It’s developing lead candidate gevokizumab with French drugmaker Servier. The firm partners on therapeutics for infectious disease, inflammatory ailments, and autoimmune conditions and receives royalties on drugs developed from licensing its technologies. XOMA has collaborative agreements with pharma companies Takeda Pharmaceutical and Novartis; it also has metabolic and oncology candidates.

Company Overview
The VERIFIED™ Group of Companies uses cookies to improve your experience on our website. By browsing this website, you agree to our use of same.

Sign in

Sign Up

Forgotten Password